Comparison of intravenous palivizumab and standard of care for treatment of respiratory syncytial virus infection in mechanically ventilated pediatric patients

Journal of Pediatric Pharmacology and Therapeutics

Volumn 21, Issue 2, 2018, Pages 146-154

  Helmink, Brady J ^a   Ragsdale, Carolyn E ^b   Peterson, Evan J ^c   Merkel, Kathryn G ^b  

^a University Medical Center Brackenridge   (United States)

^b DELL CHILDREN S MEDICAL CENTER OF CENTRAL TEXAS   (United States)

^c Seton Medical Center Austin   (United States)

Author keywords

Mechanical ventilation; Palivizumab; Respiratory syncytial virus; Standard of care

Indexed keywords

EID: 85048935783     PISSN: 15516776     EISSN: 2331348X     Source Type: Journal    
DOI: 10.5863/1551-6776-21.2.146     Document Type: Article

References (23)

1. Dawson-Caswell M, Muncie HL. Respiratory syncytial virus infection in children. Am Fam Physician. 2011;83(2):141-146.
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med.2009;360(6):588-598.
3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and metaanalysis. Lancet. 2010;375(9725):1545-1555.
4. Byington CL, Wilkes J, Korgenski K, et al. Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics. 2015;135(1);e24-e31.
5. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements--modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701.
6. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): frequently asked questions, 2008. http://www.cdc.gov/RSV/about/faq.html. Accessed January 2, 2016.
7. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774-1793.
8. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474-e1502.
9. Meert KL. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med. 1994;22(4):566-572.
10. Guerguerian AM, Gauthier M, Lebel MH, et al. Ribavirin in ventilated respiratory syncytial virus bronchiolitis: a randomized, placebo-controlled trial. Am J Resp Crit Care Med. 1999;160(3):829-834.
11. Hall CB. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. London, UK: Churchill Livingstone; 2009:2207-2221.
12. Virazole [prescribing information]. Bridgewater, NJ: Valeant; 2013.
13. Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009;14(2):75-85.
14. Kneyber M, Moll HA, de Groot R. Treatment and prevention of respiratory syncytial virus infection. Eur J Pediatr. 2000;159(6):399-411.
15. Johnson S, Oliver C, Prince G, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215-1224.
16. Sáez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23(8):707-712.
17. Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178(6):1555-1561.
18. Chávez-Bueno S, Mejías A, Merryman RA, et al. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J. 2007;26(12):1089-1093.
19. Synagis [prescribing information]. Gaithersburg, MD: MedImmune, Inc; 2013.
20. Purcell K, Fergie J. Driscoll children’s hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J. 2004;23(5):418-423.
21. Purcell K, Fergie J. Concurrent serious bacterial infections in 2396 infants and children hospitalized with respiratory syncytial virus lower respiratory tract infections. Arch Pediatr Adolesc Med. 2002;156(4):322-324.
22. Henrickson KJ, Hall CB. Diagnostic assays for respiratory syncytial virus disease. Pediatr Infect Dis J. 2007;26(11):S36-S40.
23. American Academy of Pediatrics Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Policy statement: updated guidance for palivizumab prophylaxis among infants and young children atincreased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):620-638.